A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK as early as autumn, thanks to a £1.9million award from the UK government
The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively
The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways
Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies
The new kits are based on the technology of the PerkinElmer New Coronavirus Nucleic Acid Detection Kit
A Presidential award-winning laboratory has developed a new technology to address one of the most pressing challenges in nanomedicine
Watch this on-demand webinar to gain insight on how advanced flow cytometry and live-cell analysis can facilitate faster drug development
Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants
The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel
Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
It is the first and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology
The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials
The collaboration is the first larger scale production run of Apta-1 as a non-GMP material, intended for use in GLP toxicology studies
The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system
